Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vildagliptin dihydrate (LAF237 dihydrate) is a powerful and stable dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating selectivity with an IC50 of 3.5 nM in human Caco-2 cells. This compound exhibits exceptional oral bioavailability and significant antihyperglycemic activity [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 2,140.00 | |
50 mg | 6-8 weeks | $ 2,785.00 | |
100 mg | 6-8 weeks | $ 3,520.00 |
Description | Vildagliptin dihydrate (LAF237 dihydrate) is a powerful and stable dipeptidyl peptidase IV (DPP-IV) inhibitor, demonstrating selectivity with an IC50 of 3.5 nM in human Caco-2 cells. This compound exhibits exceptional oral bioavailability and significant antihyperglycemic activity [1]. |
In vitro | Vildagliptin enhances beta cell longevity by preventing apoptosis (cell death) and encouraging cell proliferation [2]. |
In vivo | Vildagliptin, administered orally at doses of 35 mg/kg once daily via gavage, effectively increases plasma active GLP-1 levels in the islets of db/db mice, as shown by elevated GLP-1 levels from 11.69±0.44 to 22.63±1.19 after 6 weeks. In a similar vein, when given orally at a dosage of 10 μmol/kg to obese male Zucker rats, vildagliptin significantly reduces glucose excursions and enhances insulin secretion. These findings demonstrate vildagliptin's potential in modulating glucose metabolism and insulin secretion in different animal models of diabetes. |
Molecular Weight | 339.436 |
Formula | C17H29N3O4 |
CAS No. | 2133364-01-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vildagliptin dihydrate 2133364-01-7 inhibitor inhibit